Craig-Hallum initiated coverage of Immunome (IMNM) with a Buy rating and $26 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment
- Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls
- Immunome initiated with an Outperform at Evercore ISI
- Immunome’s Promising Pipeline and Financial Stability Justify Buy Rating
- Immunome Advances Cancer Therapy Pipeline Amid Financial Loss